BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 17351441)

  • 1. Outcomes of Acinetobacter baumannii infection in critically ill burned patients.
    Trottier V; Segura PG; Namias N; King D; Pizano LR; Schulman CI
    J Burn Care Res; 2007; 28(2):248-54. PubMed ID: 17351441
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Outcomes of Acinetobacter baumannii infection in critically ill surgical patients.
    Trottier V; Namias N; Pust DG; Nuwayhid Z; Manning R; Marttos AC; Dunham MB; Schulman CI; McKenney MG
    Surg Infect (Larchmt); 2007 Aug; 8(4):437-43. PubMed ID: 17883360
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Acinetobacter baumannii: an important pathogen with multidrug resistance in newborns].
    Celik IH; Demirel G; Tatar Aksoy H; Saygan S; Canpolat FE; Uras N; Oğuz SS; Erdeve O; Dilmen U
    Mikrobiyol Bul; 2011 Oct; 45(4):716-22. PubMed ID: 22090302
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk factors and outcome analysis of acinetobacter baumannii complex bacteremia in critical patients.
    Lee HY; Chen CL; Wu SR; Huang CW; Chiu CH
    Crit Care Med; 2014 May; 42(5):1081-8. PubMed ID: 24394630
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Colistin and rifampicin compared with colistin alone for the treatment of serious infections due to extensively drug-resistant Acinetobacter baumannii: a multicenter, randomized clinical trial.
    Durante-Mangoni E; Signoriello G; Andini R; Mattei A; De Cristoforo M; Murino P; Bassetti M; Malacarne P; Petrosillo N; Galdieri N; Mocavero P; Corcione A; Viscoli C; Zarrilli R; Gallo C; Utili R
    Clin Infect Dis; 2013 Aug; 57(3):349-58. PubMed ID: 23616495
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Colistin-based treatment for extensively drug-resistant Acinetobacter baumannii pneumonia.
    Khawcharoenporn T; Pruetpongpun N; Tiamsak P; Rutchanawech S; Mundy LM; Apisarnthanarak A
    Int J Antimicrob Agents; 2014 Apr; 43(4):378-82. PubMed ID: 24613422
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comparison of clinical and microbiological efficacy of antibiotic regimens against Acinetobacter baumannii.
    Ackerman BH; Haith LR; Patton ML; Guilday RE; Reigart CL; Stair-Buchmann M
    J Burn Care Res; 2013; 34(4):403-12. PubMed ID: 23237825
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epidemiology and impact of imipenem resistance in Acinetobacter baumannii.
    Lautenbach E; Synnestvedt M; Weiner MG; Bilker WB; Vo L; Schein J; Kim M
    Infect Control Hosp Epidemiol; 2009 Dec; 30(12):1186-92. PubMed ID: 19860563
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preventing strategy of multidrug-resistant Acinetobacter baumanii susceptible only to colistin in cardiac surgical intensive care units.
    Mastoraki A; Douka E; Kriaras I; Stravopodis G; Saroglou G; Geroulanos S
    Eur J Cardiothorac Surg; 2008 Jun; 33(6):1086-90. PubMed ID: 18339553
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Emergence in Taiwan of novel imipenem-resistant Acinetobacter baumannii ST455 causing bloodstream infection in critical patients.
    Lee HY; Huang CW; Chen CL; Wang YH; Chang CJ; Chiu CH
    J Microbiol Immunol Infect; 2015 Dec; 48(6):588-96. PubMed ID: 26055692
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aerosolized colistin for the treatment of multidrug-resistant Acinetobacter baumannii pneumonia: experience in a tertiary care hospital in northern Taiwan.
    Lin CC; Liu TC; Kuo CF; Liu CP; Lee CM
    J Microbiol Immunol Infect; 2010 Aug; 43(4):323-31. PubMed ID: 20688293
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epidemiologic, clinical, and economic evaluation of an outbreak of clonal multidrug-resistant Acinetobacter baumannii infection in a surgical intensive care unit.
    Young LS; Sabel AL; Price CS
    Infect Control Hosp Epidemiol; 2007 Nov; 28(11):1247-54. PubMed ID: 17926275
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk factors of mortality in patients with carbapenem-resistant Acinetobacter baumannii bacteremia.
    Liu CP; Shih SC; Wang NY; Wu AY; Sun FJ; Chow SF; Chen TL; Yan TR
    J Microbiol Immunol Infect; 2016 Dec; 49(6):934-940. PubMed ID: 25553994
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical efficacy and safety of the combination of colistin plus vancomycin for the treatment of severe infections caused by carbapenem-resistant Acinetobacter baumannii.
    Garnacho-Montero J; Amaya-Villar R; Gutiérrez-Pizarraya A; Espejo-Gutiérrez de Tena E; Artero-González ML; Corcia-Palomo Y; Bautista-Paloma J
    Chemotherapy; 2013; 59(3):225-31. PubMed ID: 24356297
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Attributable mortality of imipenem-resistant nosocomial Acinetobacter baumannii bloodstream infection.
    Jamulitrat S; Arunpan P; Phainuphong P
    J Med Assoc Thai; 2009 Mar; 92(3):413-9. PubMed ID: 19301737
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictors of mortality in Acinetobacter baumannii bacteremia.
    Chen HP; Chen TL; Lai CH; Fung CP; Wong WW; Yu KW; Liu CY
    J Microbiol Immunol Infect; 2005 Apr; 38(2):127-36. PubMed ID: 15843858
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multidrug-resistant Acinetobacter baumannii infection among neonates in a neonatal intensive care unit at a medical center in central Taiwan.
    Wei HM; Hsu YL; Lin HC; Hsieh TH; Yen TY; Lin HC; Su BH; Hwang KP
    J Microbiol Immunol Infect; 2015 Oct; 48(5):531-9. PubMed ID: 25442873
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictors of mortality in patients with extensively drug-resistant Acinetobacter baumannii pneumonia receiving colistin therapy.
    Choi IS; Lee YJ; Wi YM; Kwan BS; Jung KH; Hong WP; Kim JM
    Int J Antimicrob Agents; 2016 Aug; 48(2):175-80. PubMed ID: 27423416
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of the clinical efficacy between tigecycline plus extended-infusion imipenem and sulbactam plus imipenem against ventilator-associated pneumonia with pneumonic extensively drug-resistant Acinetobacter baumannii bacteremia, and correlation of clinical efficacy with in vitro synergy tests.
    Jean SS; Hsieh TC; Hsu CW; Lee WS; Bai KJ; Lam C
    J Microbiol Immunol Infect; 2016 Dec; 49(6):924-933. PubMed ID: 26341302
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Colistin-tigecycline versus colistin-imipenem-cilastatin combinations for the treatment of Acinetobacter baumannii ventilator-acquired pneumonia: a prognosis study.
    Chaari A; Pham T; Mnif B; Chtara K; Medhioub F; Baccouche N; Bahloul M; Hammami A; Bouaziz M
    Intensive Care Med; 2015 Nov; 41(11):2018-9. PubMed ID: 26264246
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.